Up next

Survivorship

This is the last episode of our core curriculum series. In this episode we discuss cancer survivorship as it relates to gynecologic oncology. Additionally we provide a framework for surveillance visits as well the general timing based on primary malignancy. We also give a brief o ...  Show more

Clinical Trial Design

In this episode, we describe the different types of clinical trials, outline the phases of drug development trials, describe the options for outcomes measures, explore the use of patient reported outcomes measures, and review the process of clinical trial enrollment including bes ...  Show more

Recommended Episodes

Episode 073: Management of Early Stage Diffuse Large B-Cell Lymphoma (DLBCL)
The Fellow on Call: The Heme/Onc Podcast

This week, we continue our conversation about DLBCL, this time focusing our attention on the management of early stage disease.

If you have not done so, we highly recommend you listen to our ...

  Show more

Episode 122: AML Series, Pt 8 - AML Maintenance Therapies
The Fellow on Call: The Heme/Onc Podcast

This week, we continue our series focusing on acute myeloid leukemia. In this episode, we talk about maintenance therapies in AML.

Episode contents:

- A recap of cytarabine consolidation

- Why do we do maintenance therapy?

- What are hypomethylating a ...

  Show more

Episode 074: Management of Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL)
The Fellow on Call: The Heme/Onc Podcast

This week, we continue our conversation about DLBCL, this time focusing our attention on the management of early stage disease.

In this week’s episode, we delve into the management of advance ...

  Show more

Episode 120: AML Series, Pt 6 - AML Consolidation: Therapeutic Approaches
The Fellow on Call: The Heme/Onc Podcast

This week, we move to our next phases of therapy for AML, which are consolidation and maintenance. Be sure to check out our prior episodes for a discussion on initial workup and how we incorporate recurrent genetic abnormalities into how we think about AML. Check out figure 1 ...

  Show more